Medicare Now Covers Weight-Loss Drugs for the First Time — What Seniors Need to Know
Finn's Take· TL;DR- Medicare now covers GLP-1 weight-loss drugs for eligible seniors at $50/month copay through a temporary demonstration program starting today.
- Eligible beneficiaries must have BMI of 35+ or 30-34.99 with qualifying conditions like heart disease, and participate in lifestyle programs.
- Program covers several million of roughly 15-20 million qualifying Medicare beneficiaries; infrastructure capacity and prior authorization delays pose implementation risks ahead.
A Historic Shift in Medicare Coverage Begins Today
Millions of older Americans on Medicare are now receiving a benefit that has never existed before: coverage of obesity drugs. Starting today, July 1, eligible beneficiaries can get GLP-1 medications to treat obesity for a copay of just $50 per month. For many seniors who have struggled to afford these treatments on fixed incomes, it's a long-awaited turning point.
Drugs like Wegovy and Zepbound were previously priced at more than $1,000 a month, putting them out of reach for countless older Americans. Doctors treating these patients describe the stakes as urgent. "Most of these patients that I wanted to start on this medication are ticking time bombs," said Dr. Catherine Varney, obesity medicine director at the University of Virginia. "They've got prediabetes, high blood pressure, high cholesterol, all these cardiac risk factors that are leading to heart attack and stroke."
How the Medicare GLP-1 Bridge Program Works
The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. Medicare is prohibited by law from covering weight-loss drugs, but the Centers for Medicare and Medicaid Services is allowed to run short-term demonstration projects to test new payment and coverage models. The Bridge program is the mechanism that makes this possible — for now.
The program gives eligible Part D plan members access to Foundayo®, Wegovy® (injection or tablet), or Zepbound® (KwikPen®) weight loss medications for a $50 copayment for each 30-day supply. To access coverage, a doctor must submit a prior authorization request and the prescription to a CMS central processor. That processor reviews the documentation to ensure the patient qualifies, and once approved, pays the claim so the pharmacy can release the medication.
The program is available nationwide — including all U.S. states and territories — to Medicare Part D enrollees who have a body mass index (BMI) of 35 or more, or a BMI between 30 and 34.99 combined with at least one qualifying condition such as diastolic heart failure or uncontrolled high blood pressure. Providers must also certify that patients are using the GLP-1 drug as part of a lifestyle program that focuses on diet and exercise.
The Scale of the Opportunity — and the Challenges Ahead
There are more than 69 million beneficiaries in Medicare, and "several million" are expected to access the drugs through the Bridge program, according to Chris Klomp, director of Medicare and deputy administrator of CMS. The potential pool is even larger: roughly 15 million to 20 million older adults in Medicare are estimated to qualify for weight-loss drugs, according to Novo Nordisk and Eli Lilly.
The launch could unleash significant pent-up demand for obesity drugs, potentially creating new pressures for physicians, pharmacies, and the prior authorization process — risks that could delay older Americans from getting their hands on the medications. The healthcare system is already stretched thin, with many Medicare beneficiaries facing long waits for appointments. Experts are watching closely to see whether the infrastructure can keep pace with demand.
What Comes Next — and Why It Matters
The Bridge effort is part of a deal that the Trump administration announced in November with drugmakers Eli Lilly and Novo Nordisk to reduce the cost of their blockbuster anti-obesity medications. CMS announced in May 2026 that the Part D portion of the BALANCE Model — the longer-term replacement program — will be delayed indefinitely, and that the GLP-1 Bridge will be extended through December 31, 2027.
The rollout may not be smooth initially, and the future of coverage remains unclear after the program expires at the end of 2027. The Congressional Budget Office projected that expanding coverage would cost the federal government $35 billion between 2026 and 2034. Whether Congress ultimately acts to make obesity drug coverage a permanent part of Medicare will define the long-term health trajectory of millions of American seniors — and the financial future of the program itself.